Please enable JavaScript.
Coggle requires JavaScript to display documents.
Multidrug Transporters (Drug Efflux Pumps & Other Efflux Proteins (ABC…
Multidrug Transporters
-
Antibiotic Resistance
How it arises
Arises rapidly, most antibiotics have observed resistance mechanisms to them within 15 years
Can be tracked through genomic sequencing to determine where mutations have arisen (C. difficile - He, 2012, Nature Genetics)
-
-
Experiments have been conducted on the evolution of resistance mechanisms to see how they develop (Baym, 2016, Science)
-
Morbidostat experiments (Toprak, 2012, Nature Genetics)
IC50 increases dramatically over time no matter what antibiotic is used (showing resistance will always develop in right conditions
-
Different drugs affect different genes to different amounts - TMP causes mutations predominantly folic acid synthesis, DOX mutations are mostly in transcription & translation, CHL are tyipcally in membrane proteins (acrB and promoter of Cmr), thought to be because it has double the partition coefficient of DOX
There appears to be some order in which this arises, as is shown in TMP resistance
-
Charity work (Lee, 2010, Nature)
Shows that populations can survive higher doses than isolates can and that populations are dominated by less resistant isolates
-
Antibiotic challenge results in an increase in indole production - this is only seen in the highly resistant isolates, seen in gel shift assays as a band corresponding to tryptophanase production
Adding indole to the less resistant isolates increased resistance in them. This is because indole stimulates antibiotic-tolerance mechanisms in the population to allow non-resistant individuals to survive
-
-
How it functions
-
-
Trimethoprim - variety of methods (Baym, 2016, Science)
Mutations in dnaQ/DNAPolIII, most often at Q97(T/N/S), typically non-synonymous mutations
Several mutatinos also seen in folA/DHFR, this is the most commonly mutated gene
-
Non-replicating,
multidrug-tolerant bacteria
First described by Joseph Bigger (1944) - they appear to exist in that state already rather than being induced by the penicilin
-
A balance of duration of treatment and [antibiotic] can be used to model tolerant and resistant bacteria - tolerant survive for longer, resistant survive at higher [antibiotic] (Fridman, 2014, Nature) - this shows that a minimum dosage and duration of time is required for 99% of bacteria to be killed
These bacteria are described as 'tolerant' and can be induced by infrequent dosing with an antibiotic. Mutations are termed tbl for 'tolerance by lag'
Underlying this is an extension in single-cell lag-times (time before the cells divide). These matched the duration of the antibiotic-exposure interval
These tbl mutations are along two major modules. Toxin-antitoxin modules and aminoacyl-transfer RNA synthetase
Toxin-antitoxin modules (Harms, 2018, Molecular Cell)
(p)ppGpp
This is relied upon heavily. It is increased as part of the "stringent response" and the persistence phenotype depends on it, as do other types of multidrug resistance in biofilms
persistence also depends on Lon protease, Pi and toxin-antitoxins
High [(p)ppGpp] inhibit exopolyphosphatase (PPX) activity. PPX stimulates Lon protease to degrade antitoxins. This allows antitoxins to function and inhibit mRNA synthesis/translation. Toxins also act as TFs for a gene that encodes both toxins and antitoxins, resulting in a dynamic equilibrium forming
Toxins slow the cell cycle by acting on many parts of the cell - DNA gyrase, aa-tRNA synthetase, ribosomes.
They also dissipate electrochemical proton gradients, causing depletion of the ATP pool
High persister (hip) mutants of myobacterium tuberculosis have been observed when exposing them to two antibiotics (Torrey, 2016, PLoS One)
Chemical mutagenesis is carried out and then hip mutants are selected by treatment with rifampin and streptomycin
Mutants had:
Reduced PDIM cell wall lipid and virulence factor expression
Mutations in regulators of feast and famine regulation
Decreasde phospholipid biosynthesis and lipid catabolism - preventing cell division
Upregulation of toxin-antitoxin module expression
Studying these in bacteria showed that some bacteria can survive inside macrophages (Helaine, 2010, PNAS) using conditional dyes to show whether cells are dead or dormant
This is the result of a dormancy response - unclear how much the effect is the result of reduced [nutrients] or mutations
Studies have looked at this in more detail, showing how efflux pump Rv1258c (MFS transporter) might confer rifampicin tolerance within macrophages (Adams, 2014/2011, J Infect Diseases/Cell)
May be the result of transporters being upregulated. Evidence suggests a link between the two. Increase in efflux pumps --> increase in signalling molecules released --> shortened growth phase (Yang, 2006, PNAS)
Is a significant health concern, particularly in Asia & Africa
Why it arises
Administered incorrectly (too short or too long) - this is made worse by lack of alignment between countries
Longitudinal prize is ongoing for a test that can easily determine if an infection is bacterial or not and prevent incorrect administration
-
-
Interconnectedness of the world allows antibiotics and antibiotic resistance genes to circulate readily in the environment, spreading resistance and allowing for more mutations
Resistance genes spread typically by first jumping to a high copy plasmid to create a large number of positive cells in a colony and then horizontally transferring to another species
Genetic exchange in the gut is very common, both in animals and humans due to the large number of bacteria there
Antibiotics
-
Beta-lactam antibiotics
-
Cephalosporins are effective against both gram -ve and +ve bacteria, these are first-line therapies
Monobactams are beta-lactamase resistant and are sometimes used when hypersensitivity to pencillins arise, not effective against P.aeruginosa
Carbapenems are used for treatment of multi-drug resistant bacteria and is primarily for those hospitilised through infection - they are highly beta-lactamase resistant
Tariquidar (ABCB1/pgp-blocker) has shown some efficacy against doxorubicin-resistant tumouors (Pajic, 2009, Cancer Res). In fact it appears that its expression levels may cause the resistance in the first place - mRNA studies
-
-
-